Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-25

Study Completion Date

2023-05-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase I trial studies the best dose and side effects of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel)/rituximab-coated nanoparticle AR160 in treating patients with B-cell non-Hodgkin lymphoma that has come back (relapsed) or is not responding to treatment (refractory). Nab-paclitaxel/rituximab-coated nanoparticle AR160 is a combination of paclitaxel albumin-stabilized nanoparticle formulation and rituximab. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with rituximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving paclitaxel albumin-stabilized nanoparticle formulation and rituximab may work better in treating patients with B-cell non-Hodgkin lymphoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00244985

Lymphoma

COMPLETED PHASE1/PHASE2

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

NCT01938001

Lymphoma, Non-Hodgkin

COMPLETED PHASE3

Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

NCT00058461

B-cell Childhood Acute Lymphoblastic Leukemia Childhood Burkitt Lymphoma Childhood Diffuse Large Cell Lymphoma +6 more

TERMINATED PHASE2

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

NCT01232556

Lymphoma, Non-Hodgkin

TERMINATED PHASE3

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

NCT05583149

Refractory Aggressive B-cell Lymphomas Refractory B-Cell Non-Hodgkin Lymphoma Aggressive B-cell NHL +10 more

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. To establish the maximum tolerated dose (MTD) of nab-paclitaxel/rituximab-coated nanoparticle AR160 (AR160) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). (Phase I)

SECONDARY OBJECTIVES:

I. To assess the toxicity and safety of AR160. II. To assess complete response rate (CR) progression free survival (PFS), and overall survival (OS) of AR160 with relapsed/refractory B-cell NHL.

CORRELATIVE RESEARCH OBJECTIVE:

I. Evaluate pharmacokinetics (PK) of AR160 in two formal PK studies, dose 1 of cycle 1 (48 hours \[h\] PK analysis) and dose 1 of cycle 2 (24h PK analysis). As of Amendment 4, PKs will no longer be collected.

OUTLINE: This is a dose-escalation study.

Patients receive nab-paclitaxel/rituximab-coated nanoparticle AR160 intravenously (IV) over 30-60 minutes on days 1, 8, and 15. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 6 months for up to 2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Aggressive Non-Hodgkin Lymphoma Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Aggressive Non-Hodgkin Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Refractory Small Lymphocytic Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (AR160)

Patients receive nab-paclitaxel/rituximab-coated nanoparticle AR160 IV over 30-60 minutes on days 1, 8, and 15. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Group Type EXPERIMENTAL

Laboratory Biomarker Analysis

Intervention Type OTHER

Correlative studies

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160

Intervention Type DRUG

Given IV

Pharmacological Study

Intervention Type OTHER

Correlative studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Laboratory Biomarker Analysis

Correlative studies

Intervention Type OTHER

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160

Given IV

Intervention Type DRUG

Pharmacological Study

Correlative studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Abraxane coated with Rituximab Abraxane Coated with Rituximab 160nm Nanoparticle Abraxane/Rituxan 160 Complex AR160

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>= 18 years.
* Histological confirmation of relapsed/refractory B-cell NHL, CD20+

* NOTE: patients with small lymphocytic lymphoma (SLL) are eligible however patients with chronic lymphocytic leukemia (CLL) are not eligible
* Waldenstrom macroglobulinemia patients are not eligible; aggressive lymphoma patients who are transplant eligible must have undergone a transplant
* The biopsy confirming relapse can be up to 24 weeks prior to registration as long as there is no intervening therapy
* Measurable disease (at least 1 lesion of \>= 1.5 cm in one diameter) as detected by computed tomography (CT) or the CT images of the positron emission tomography (PET)/CT. Skins lesions can be used if the area is greater than or equal to 2 cm in at least one diameter and photographed with a ruler
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
* Absolute neutrophil count (ANC) \>= 1500/mm\^3 (obtained =\< 14 days prior to registration)
* Platelet count \>= 75,000/mm\^3 (obtained =\< 14 days prior to registration)
* Hemoglobin \>= 8.0 g/dL (obtained =\< 14 days prior to registration)
* Total bilirubin =\< 1.5 X upper limit of normal (ULN) or if total bilirubin is \> 1.5 X ULN, the direct bilirubin =\< ULN (obtained =\< 14 days prior to registration)
* Alkaline phosphatase =\< 3 X ULN unless due to direct lymphoma involvement, and then =\< 5 X ULN (obtained =\< 14 days prior to registration)
* Aspartate transaminase (AST) =\< 3 X ULN unless due to direct lymphoma involvement, and then =\< 5 X ULN (obtained =\< 14 days prior to registration)
* Calculated creatinine clearance must be \>= 30 ml/min using the Cockcroft-Gault formula (obtained =\< 14 days prior to registration)
* Life expectancy \>= 3 months
* Ability to provide written informed consent
* Willing to return to enrolling institution for follow-up (during the treatment phase of the study)
* Willing to provide blood samples for correlative research purposes
* Failed or are intolerant to 2 or more lines of established therapy or for whom no other treatment options are available in the opinion of the investigator
* Negative pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only
* Disease-free of prior invasive malignancies for \> 5 years prior to registration

* Note: Exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix

Exclusion Criteria

* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:

* Pregnant women
* Nursing women
* Men or women of childbearing potential who are unwilling to employ adequate contraception
* Active central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells that requires therapy
* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Received most recent therapy =\< 4 weeks prior to registration; NOTE: use of systemic steroid therapy is allowed pretreatment
* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
* Patients with \>= 25% of the bone marrow radiated for other diseases
* Other medical conditions including but not limited to:

* History of liver disease such as cirrhosis, chronic active hepatitis, chronic persistent hepatitis or hepatitis B or C
* Active infection requiring parenteral antibiotics
* New York Heart Association class II-IV congestive heart failure (serious cardiac arrhythmia requiring medication)
* Myocardial infarction or unstable angina =\< 6 months prior to registration
* Congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
* Clinically significant peripheral vascular disease
* History of CNS disease (e.g., primary brain tumor, vascular abnormalities, etc.), clinically significant stroke or transient ischemic attack (TIA) =\< 6 months prior to registration, seizures not controlled with standard medical therapy
* Neuropathy ˃ grade 3
* Administration of strong CYP2C8 or CYP3A4 inhibitors or inducers =\< 10 days prior to registration

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No